[go: up one dir, main page]

YU34796A - Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže - Google Patents

Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže

Info

Publication number
YU34796A
YU34796A YU34796A YU34796A YU34796A YU 34796 A YU34796 A YU 34796A YU 34796 A YU34796 A YU 34796A YU 34796 A YU34796 A YU 34796A YU 34796 A YU34796 A YU 34796A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical compositions
hydroxy
alkyl
indole
carbonyl
Prior art date
Application number
YU34796A
Other languages
English (en)
Inventor
Bernard Hulin
Judith Lee Treadway
William Holt Martin
Denis Jay Hoover
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU34796A publication Critical patent/YU34796A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na izvesne indol-2-karboksamide, korisne kao inhibitore glikogenfosforilaze i njihove farmaceutske kompozicije. Ova nova jedinjenja imaju formulu gde je tačkasta (...) linija proizvoljna veza; A je -C(H)=, -C(halogen)- ili -N=; R1, R10 i R11 su H, halogen, cijano, C1-C4 alkil ili fluorometil; R4 je H, metil, etil, n-propil ili hidroksi (C1-C3)alkil; R2 i R3 su H, R5 je hidroksi; R6 je C(O)NR8R9 i R7 je H; gde R8 predstavlja H, (C1-C6)alkil, hidroksi ili (C1-C8)alkoksi, a R9 predstavlja H, ciklo(C3-C8)alkil ili hidroksi.
YU34796A 1995-06-06 1996-06-05 Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže YU34796A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002223625A CA2223625C (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PCT/IB1995/000443 WO1996039385A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
YU34796A true YU34796A (sh) 1999-07-28

Family

ID=25679897

Family Applications (1)

Application Number Title Priority Date Filing Date
YU34796A YU34796A (sh) 1995-06-06 1996-06-05 Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže

Country Status (40)

Country Link
US (1) US6297269B1 (sh)
EP (1) EP0832066B1 (sh)
JP (1) JP3068200B2 (sh)
CN (1) CN1374082A (sh)
AP (2) AP9600817A0 (sh)
AT (1) ATE205477T1 (sh)
AU (1) AU700887B2 (sh)
BG (1) BG62566B1 (sh)
BR (1) BR9602626A (sh)
CA (1) CA2223625C (sh)
CO (1) CO4700453A1 (sh)
CZ (1) CZ289233B6 (sh)
DE (1) DE69522718T2 (sh)
DK (1) DK0832066T3 (sh)
DZ (1) DZ2036A1 (sh)
ES (1) ES2161291T3 (sh)
FI (1) FI974437A0 (sh)
GR (1) GR3037075T3 (sh)
HR (1) HRP960266B1 (sh)
HU (1) HUP9601285A3 (sh)
IL (1) IL118236A0 (sh)
IS (1) IS1846B (sh)
LV (1) LV11614B (sh)
MA (1) MA23874A1 (sh)
MX (1) MX9709874A (sh)
NO (1) NO307335B1 (sh)
NZ (1) NZ286736A (sh)
OA (1) OA10459A (sh)
PL (1) PL314603A1 (sh)
PT (1) PT832066E (sh)
RU (1) RU2159613C2 (sh)
SG (1) SG45481A1 (sh)
SI (1) SI9600163A (sh)
SK (1) SK72096A3 (sh)
TN (1) TNSN96075A1 (sh)
TR (1) TR199600478A1 (sh)
TW (1) TW450961B (sh)
WO (1) WO1996039385A1 (sh)
YU (1) YU34796A (sh)
ZA (1) ZA964646B (sh)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
IL131659A (en) 1997-04-15 2005-07-25 Csir Pharmaceutical compositions having appetite suppressant activity
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
CN1230171C (zh) * 1997-06-18 2005-12-07 史密丝克莱恩比彻姆有限公司 用噻唑烷二酮和二甲双胍治疗糖尿病
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
US6096778A (en) * 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
US6150378A (en) * 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1073440B1 (en) * 1998-05-01 2004-10-20 Eli Lilly And Company sPLA 2 INHIBITOR ESTERS
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6686335B1 (en) 1998-09-22 2004-02-03 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) * 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
ES2211454T3 (es) * 1999-09-30 2004-07-16 Pfizer Products Inc. Pirrolilamidas como inhibidores de la colageno fosforilasa.
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
RU2002111660A (ru) 1999-11-04 2003-11-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Непептидные замещенные бензотиазепины в качестве антагонистов вазопрессина
EP1741447B1 (en) 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2001062295A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicaments contenant des ingredients actifs combines
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
WO2002036066A2 (en) * 2000-11-01 2002-05-10 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
US6821960B2 (en) * 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030037045A1 (en) * 2001-05-21 2003-02-20 Ian Melhado Distributed computing environment for recognition of proteomics spectra
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
CA2465382A1 (en) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
EP1469873A4 (en) 2001-11-26 2007-10-03 Tufts College PEPTIDOMIMETIC INHIBITORS FROM BEHIND PROLIN SPLENDING ENZYMES
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
JP2005514460A (ja) * 2002-01-18 2005-05-19 ファイザー・プロダクツ・インク グリコーゲンホスホリラーゼ阻害剤を製造するための中間体
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
MXPA03000966A (es) * 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
ATE443041T1 (de) * 2002-07-11 2009-10-15 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
BR0316099A (pt) 2002-11-07 2005-09-27 Pfizer Prod Inc Agentes antidiabéticos
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
FR2847471B1 (fr) * 2002-11-25 2006-12-29 Expanscience Lab Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
BRPI0409465A (pt) * 2003-04-17 2006-05-02 Pfizer Prod Inc derivados de carboxamida como agentes antidiabéticos
WO2004096768A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
UA84146C2 (ru) * 2003-05-21 2008-09-25 Прозидион Лимитед Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2524916T3 (es) 2003-11-12 2014-12-15 Sino-Med International Alliance, Inc. Compuestos heterocíclicos de ácido borónico
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
JP2007527903A (ja) * 2004-03-08 2007-10-04 プロシディオン・リミテッド インドール−２−カルボン酸ヒドラジド化合物
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
HRP20140091T4 (hr) 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
MX2008009581A (es) * 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
DE102006042147A1 (de) * 2006-09-06 2008-03-27 Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
MX2009002047A (es) * 2006-09-13 2009-03-06 Sanofi Aventis Derivados de isoserina para uso como inhibidores del factor ixa de la coagulacion.
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
MX2010013602A (es) 2008-06-19 2011-03-15 Takeda Pharmaceuticals Co Compuesto heterociclico y uso del mismo.
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
JP5959075B2 (ja) * 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
EP2714648B1 (en) 2011-05-31 2017-08-16 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
EP2714662B1 (en) 2011-05-31 2017-10-11 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
RU2618628C1 (ru) 2013-04-17 2017-05-05 Пфайзер Инк. Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
WO2015068156A1 (en) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
WO2015131113A1 (en) * 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA3125765A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN115583908B (zh) * 2021-07-05 2024-08-06 西北农林科技大学 一种吲哚甲酰胺类化合物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764610A (en) 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4836846A (en) 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4902708A (en) 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
HU204285B (en) 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
US5034376A (en) 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
EP0288965A2 (de) 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
EP0336356A3 (en) 1988-04-05 1991-09-25 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US4904846A (en) 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
US5010089A (en) 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
EP0431520B1 (en) 1989-12-04 1995-02-08 G.D. Searle & Co. Heterocyclic acyl aminodiol beta-amino acid derivatives
HUT61575A (en) 1990-02-09 1993-01-28 Rhone Poulenc Rorer Sa Process for producing n-acetamido-n-phenyl glycineamide derivatives and pharmaceutical compositions comprising same
WO1991013874A1 (fr) 1990-03-07 1991-09-19 Rhone-Poulenc Rorer S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
FR2678938B1 (fr) 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.

Also Published As

Publication number Publication date
BR9602626A (pt) 1998-09-01
WO1996039385A1 (en) 1996-12-12
LV11614A (lv) 1996-12-20
CO4700453A1 (es) 1998-12-29
CA2223625C (en) 2003-06-03
CZ162796A3 (en) 1996-12-11
NO307335B1 (no) 2000-03-20
DE69522718D1 (en) 2001-10-18
CZ289233B6 (cs) 2001-12-12
US6297269B1 (en) 2001-10-02
AU700887B2 (en) 1999-01-14
IS1846B (is) 2003-02-07
NO962322L (no) 1996-12-09
SK72096A3 (en) 1997-11-05
TW450961B (en) 2001-08-21
DK0832066T3 (da) 2001-11-19
GR3037075T3 (en) 2002-01-31
HUP9601285A2 (hu) 1998-09-28
NO962322D0 (no) 1996-06-05
LV11614B (en) 1997-04-20
SI9600163A (en) 1997-02-28
HRP960266B1 (en) 2002-08-31
TNSN96075A1 (fr) 2005-03-15
ATE205477T1 (de) 2001-09-15
JP3068200B2 (ja) 2000-07-24
CA2223625A1 (en) 1996-12-12
AP9600817A0 (en) 1996-07-31
HRP960266A2 (en) 1997-08-31
TR199600478A1 (tr) 1997-03-21
PL314603A1 (en) 1996-12-09
AP9600816A0 (en) 1996-07-31
RU2159613C2 (ru) 2000-11-27
BG100635A (en) 1997-09-30
MA23874A1 (fr) 1996-12-31
AU5475396A (en) 1996-12-19
HUP9601285A3 (en) 2001-04-28
DE69522718T2 (de) 2002-02-07
ZA964646B (en) 1997-12-05
AP624A (en) 1997-12-19
EP0832066B1 (en) 2001-09-12
MX9709874A (es) 1998-03-31
ES2161291T3 (es) 2001-12-01
PT832066E (pt) 2001-12-28
BG62566B1 (bg) 2000-02-29
IL118236A0 (en) 1996-09-12
FI974437A (fi) 1997-12-05
DZ2036A1 (fr) 2002-10-22
CN1374082A (zh) 2002-10-16
JPH11500445A (ja) 1999-01-12
NZ286736A (en) 2001-07-27
OA10459A (en) 2002-03-27
FI974437A0 (fi) 1997-12-05
EP0832066A1 (en) 1998-04-01
IS4345A (is) 1996-12-07
SG45481A1 (en) 1998-01-16
HU9601285D0 (en) 1996-07-29

Similar Documents

Publication Publication Date Title
YU34796A (sh) Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
DE69627377D1 (de) Inhibitoren der protein-isoprenyl-transferase
DK0876350T3 (da) Pyrazolderivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
HRP20020751B1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
EP1176958A4 (en) NEW CATHECHOLE AS AN ANTIMICROBIAL AGENT
HUP0002159A2 (hu) Eljárás peszticid hatóanyagok intermedierjeinek előállítására, az eljárásban alkalmazott új intermeierek és előállításuk
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
ATE215555T1 (de) 17-beta.-allyloxy(thio)alkyl-androstan derivative zur modulation von meiose
YU13899A (sh) Pirolidinil i pirolinil etilaminska jedinjenja kao kapa agonisti
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
HUP9903526A2 (hu) Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
HUP0401280A2 (hu) Szelektív COX-2 inhibitor hatású pirimidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK0832067T3 (da) Fremgangsmåde til omdannelse af 2,4-dichlorpyridiner til 2-aryloxy-4-chlorpyridiner
RS49829B (sr) Postupak i intermedijeri za proizvodnju piridin-2,3-dikarboksilat jedinjenja
YU78001A (sh) Derivati 6-(((aril i heteroaril)oksi)metil) naftalen-2- karboksimidamida, njihovo dobijanje i terapeutska primena
DE69316392D1 (de) Azanoradamantane
DK0596917T3 (da) Benzimidazolanthelmintika
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
NO933903L (sh)
ATE255111T1 (de) Abeo-ergolinderivate als 5ht1a liganden
HUP9902088A2 (hu) Szubsztituált 1,3-benzodioxol-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
MX9705971A (es) Producto fungicida.